Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing

Executive Summary

CEO pledges transparency and responsible pricing of J&J drugs during the company’s earnings call, while outlining its goals for US health care and tax reform. Fourth quarter performance was unspectacular, although J&J's oncology and immunology portfolios showed sales growth.

Advertisement

Related Content

Earnings Winners and Losers: BSX, EW, ABT, JNJ, SYK, ZBH
Stockwatch: Mistaken Acquisitions Dim Earnings Season
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
J&J Promotes Preventive Care, Wellness In US Health Debate
J&J's Actelion Courtship Seen Unaffected By Macitentan MAESTRO Failure
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Rx For Industry: Key Provisions Of The 21st Century Cures Act
Trump’s HHS, CMS Leadership Choices Underscore Focus On ACA Reform
Pharma Is Ready And Waiting For A Tax Holiday Under Trump
Janssen Expanding Its Disease Interception Efforts

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register